Validation & Intervention Testing for Aging, Longevity and Healthspan (VITAL-H)
Lay Description
We are looking at whether two FDA-approved medications, semaglutide and dapagliflozin, may help people stay healthier as they age. Researchers want to learn if these medications can help maintain strength, physical function, and overall health in adults ages 60 to 75. The information collected will also help researchers better understand how aging affects the body over time.
Category
- Aging and Geriatric
- Healthy Subjects Needed
- Wounds and Injuries
- IRB Number
- STUDY00002818
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Not set
Eligibility
- Eligible Ages
- -
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
• Willing to follow the study intervention regimen as instructed (dapagliflozin, semaglutide or placebo)
• Currently live independently in the community (i.e., not in a nursing home, assisted living facility, or other institutional setting)
• Body Mass Index (BMI) between 20 and 40 kg/m²
Exclusion Criteria
Study Design
Study Contact
Regulatory Point of Contact
Tiffany Cortes
210-450-8998
cortest@uthscsa.edu
Regulatory Point of Contact
Eloisa Martinez
martineze42@uthscsa.edu
Local Recruitment Point of Contact
Elena Volpi
210-562-6139
volpi@uthscsa.edu
Overall Recruitment Point of Contact
Elena Volpi
210-562-6139
volpi@uthscsa.edu
Principal Investigator
Elena Volpi